SignatureFD’s Catalyst Pharmaceutical CPRX Stock Holding History

SignatureFD’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.1K	Buy	489 +404	+475%	+$9.63K	﹤0.01%	2422
2025 Q4	$1.98K	Hold	85	–	–	﹤0.01%	2973
2025 Q3	$1.68K	Sell	85 -9	-10%	-$185	﹤0.01%	2995
2025 Q2	$2.04K	Sell	94 -72	-43%	-$1.7K	﹤0.01%	2859
2025 Q1	$4.03K	Buy	166 +72	+77%	+$1.62K	﹤0.01%	2680
2024 Q4	$1.96K	Sell	94 -11	-10%	-$236	﹤0.01%	2877
2024 Q3	$2.09K	Hold	105	–	–	﹤0.01%	2825
2024 Q2	$1.63K	Hold	105	–	–	﹤0.01%	2812
2024 Q1	$1.67K	Hold	105	–	–	﹤0.01%	2849
2023 Q4	$1.76K	Hold	105	–	–	﹤0.01%	2791
2023 Q3	$1.23K	Hold	105	–	–	﹤0.01%	2893
2023 Q2	$1.41K	Hold	105	–	–	﹤0.01%	2895
2023 Q1	$1.74K	Sell	105 -37	-26%	-$610	﹤0.01%	2843
2022 Q4	$2.64K	Buy	142 +37	+35%	+$570	﹤0.01%	2715
2022 Q3	$1K	Buy	105 +71	+209%	+$841	﹤0.01%	2932
2022 Q2	$0	Buy	+34	New	+$249	﹤0.01%	3146
2014 Q3	–	Sell	-3,000	Closed	-$8K	–	738
2014 Q2	$8K	Buy	+3,000	New	+$6.41K	﹤0.01%	488

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SignatureFD's CPRX Position: Q1 2026 in Review

SignatureFD increased its Catalyst Pharmaceutical (CPRX) stake by 475% in Q1 2026, buying an estimated $9.63K and bringing the position to 489 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2422.

SignatureFD first reported a position in CPRX in Q2 2014 and has held it in 17 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

SignatureFD held 489 shares of Catalyst Pharmaceutical worth $12.1K as of Q1 2026.
SignatureFD bought 404 Catalyst Pharmaceutical shares in Q1 2026, an estimated $9.63K.
Catalyst Pharmaceutical made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #2422 holding.
SignatureFD first reported a position in Catalyst Pharmaceutical in Q2 2014 and has held it in 17 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.